As Sanofi's SERD falls, Menarini’s advances with EU review Immuron culls COVID drug work as new variants, a competitive market renders asset DOA US drug pricing reform in Inflation Reduction Act could harsh pharma's credit, Moody's says Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment 'The Top Line': 2 deaths put Novartis' SMA gene therapy in the safety spotlight, what's behind AstraZeneca's next-gen CAR-T therapy tactics and more Eargo, GN Hearing, Best Buy to step up hearing aid offerings amid FDA's over-the-counter ruling Children's hospitals targeted in harassment campaigns over gender-affirming care for minors Back to basics: High-tech blood pressure monitors don't outperform standard cuffs, study finds CVS, Walmart and Walgreens ordered to pay $650M in Ohio opioid suit, but some providers worry about aftermath Fierce Pharma Asia—Daiichi's ADC patent win; Roche's bet on Jemincare's PROTAC; AbbVie's CD47 retreat Chutes & Ladders—PerkinElmer's Mock dons CFO mantle at Moderna Featured Story | By Annalee Armstrong Just days ago, Sanofi sent its oral SERD for breast cancer to the trash can. But over in Italy, a small biotech is plodding forward with its own candidate, with the EU begining a regulatory review. read more |
| |
|---|
|
Top Stories By Ben Adams Australian biotech Immuron is showing up the brutal nature of COVID research: We have seen so many big-name successes from Pfizer, Moderna, AstraZeneca and Merck, we forget that there are also many casualties. read more By Fraiser Kansteiner The drug pricing provisions tucked into the Inflation Reduction Act could eventually have a credit-lowering effect on the industry at large, because pharma will largely bear the brunt of the changes, the analysts said—despite the fact that several of those measures won’t come into effect for “four or more years.” read more By Angus Liu Novartis’ multiple sclerosis therapy Gilenya was once proposed as a kidney disease treatment because of its ability to modulate S1P receptors. Although the drug failed in a clinical trial, scientists at the University of Virginia have now found an alternative way to target the same pathway. read more By Teresa Carey This week on "The Top Line," we discuss Novartis’ gene therapy Zolgensma—and the two deaths following treatment. We also hear from AstraZeneca on its strategy to get into the CAR-T space with off-the-shelf cancer cell therapies. read more By Andrea Park Many devicemakers have shown their support for the FDA ruling, since it allows them to market their products directly to consumers, cutting out multiple middlemen and potentially bringing their hearing aids to more people. read more By Dave Muoio Recent claims that Boston Children's Hospital and others offer genital surgery to minors have led to a spike in hostile messages and calls to clinicians and staff, according to hospitals and media reports. read more By Andrea Park In a rare exception to the usual rules of technological advancement, a new study published this week in JAMA Internal Medicine has found that high-tech bells and whistles haven’t contributed to any major improvement in clinical outcomes for at-home blood pressure monitors. read more By Anastassia Gliadkovskaya Though the latest judgment is expected to set a precedent for other communities trying to hold pharmacies accountable, some providers worry about the unintended consequences of potential new dispensary restrictions. read more By Angus Liu Daiichi Sankyo wins arbitration in its latest antibody-drug conjugate patent battle against Seagen. Roche buys a prostate cancer protein degrader from a Chinese company. AbbVie pulled the plug on another CD47 clinical trial in its potential $2 billion partnership with I-Mab. And more. read more By Fraiser Kansteiner,Gabrielle Masson Moderna's CFO David Meline may finally get a chance to retire as PerkinElmer's James Mock prepares to take the gig. Philips' CEO is passing the torch to an executive who's managed the company's recent recall response. Plus, Ambrx lost its CEO as the biotech takes a hard look at its pipeline. read more | | New Product Planning Summit September 19-20, 2022 | Boston, MA Join us for the ONLY conference for defining how the new product planning role and related functions make informed, value-based, data-driven decisions about products in the pipeline. Register now! |
|---|
Resources Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Speid & Associates, Inc. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 